Yilong Wu, MD

Yilong Wu, MD

Vice President
Guangdong General Hospital
Guangdong Academy of Medical Sciences
Director, Guangdong Lung Cancer Institute
Guangzhou, China

Related Videos

Does FoundationOne's comprehensive NGS have validation studies confirming accuracy across multiple alterations in a peer-reviewed journal? Video

Does FoundationOne's comprehensive NGS have validation studies confirming accuracy across multiple alterations in a peer-reviewed journal?

Does FoundationOne’s comprehensive NGS have validation studies confirming accuracy across multiple alterations in a peer-reviewed journal? Please discuss. Do you know of any other genomic profiling services that are clinically validated ...

How is genomic profiling helpful in identifying actionable molecular targets? Video

How is genomic profiling helpful in identifying actionable molecular targets?

Successful targeted cancer therapies include trastuzumab for HER2-amplified breast cancer, imatinib in Philadelphia chromosome–positive CML, erlotinib in EGFR-mutated non-small cell lung cancer and vemurafenib in BRAF-mutant melanoma. ...

In China, how does FoundationONE NGS sequencing compare to common "hotspot panels" with respect to detecting clinically actionable alterations? Video

In China, how does FoundationONE NGS sequencing compare to common "hotspot panels" with respect to detecting clinically actionable alterations?

In China, how does FoundationONE NGS sequencing compare to common “hotspot panels” with respect to detecting clinically actionable alterations? How does FoundationONE technology differ from “hotspot” panels?

What does it mean that a tumor sample has a mutation or rearrangement? Is the presence of a mutation an "all-or-none" phenomenon or are there additional levels once an alteration is identified? Video

What does it mean that a tumor sample has a mutation or rearrangement? Is the presence of a mutation an "all-or-none" phenomenon or are there additional levels once an alteration is identified?

Exactly what does it mean that a tumor sample has a mutation or rearrangement? Exactly what is being measured? Is the presence of a mutation an “all-or–none” phenomenon or are there additional quantitative levels of characterization available ...

Does hybrid capture-based next-generation sequencing (NGS) have special application for detecting actionable genomic alterations in lung adenocarcinoma? Video

Does hybrid capture-based next-generation sequencing (NGS) have special application for detecting actionable genomic alterations in lung adenocarcinoma?

Does hybrid capture-based next-generation sequencing (NGS) have special application for detecting actionable genomic alterations in lung adenocarcinoma?

For what solid tumors and hematologic malignancies has NGS genomic profiling shown to be most valuable for identifying mutations that can reliably guide the use of targeted therapy? Video

For what solid tumors and hematologic malignancies has NGS genomic profiling shown to be most valuable for identifying mutations that can reliably guide the use of targeted therapy?

For what specific solid tumors and hematologic malignancies has NGS genomic profiling shown to be most valuable for identifying mutations that can reliably guide the use of molecularly targeted therapy?

How does NGS address the changes that cancer treatment is undergoing, toward the use of molecularly targeted drugs prescribed to selected subsets of patients across multiple tumor types? Video

How does NGS address the changes that cancer treatment is undergoing, toward the use of molecularly targeted drugs prescribed to selected subsets of patients across multiple tumor types?

In what important ways does NGS address the fundamental changes that systemic cancer treatment is undergoing, i.e., toward the use of molecularly targeted drugs prescribed to selected subsets of patients across multiple tumor types?